Targeting mucosal healing in crohn's disease

Gastroenterology and Hepatology

Volumn 7, Issue 6, 2011, Pages 374-380

  Kakkar, Aarti ^a,b   Wasan, Sharmeel K ^a,b   Farraye, Francis A ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Biologic agents; Crohn's disease; Deep remission; Endoscopic remission; Immunomodulators; Mucosal healing

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISOLONE;

ABDOMINAL SURGERY; CROHN DISEASE; DISEASE ACTIVITY; HEALING; HOSPITALIZATION; HUMAN; INTESTINE MUCOSA; QUALITY OF LIFE; REMISSION; REVIEW; SYMPTOM; WOUND HEALING;

EID: 79960376353     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-483; quiz 464, 484.
2. Allez M, Lémann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long-term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol. 2002;97:947-953. (Pubitemid 34408253)
3. Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol. 2005;3:11-24. (Pubitemid 40092938)
4. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperadve course of Crohn's disease. Gastroenterology. 1990;99:956-963. (Pubitemid 20338451)
5. Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665-672.
6. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422. (Pubitemid 47187355)
7. Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab treatment results in deep remission for patients with moderate to severe ileocolonic Crohn's disease: results from EXTEND. Gastroenterology. 2010;138:S518.
8. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15:1295-1301.
9. Solberg IC, Lygren I, Jahnsen J, Vatn M, Moum B. Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease. Gut. 2008;57(suppl 2):A15.
10. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442; quiz 464.
11. D'Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667. (Pubitemid 351284485)
12. Baert F, Moortgat L, Van Assche G, et al; Belgian Inflammatory Bowel Disease Research Group; Nordi-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010;138:463-468; quiz e10-e11.
13. D'Haens G, et al. Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology. 2002;122:A-618.
14. Rutgeerts PJ, Thakkar R, Kaltenboeck A, et al. Mucosal healing predicts long-term clinical benefits for adalimumab-treated patients with Crohn's disease. Gastroenterology. 2010;138:S-85.
15. Hebuterne X, Lemann M, Coteur G, Ernault E, Colombel JF. Health-related quality of life improvements in patients with active Crohn's disease following treatment with certolizumab pegol in the MUSIC study (Ncr00297648). Am J Gastroenterol. 2010;105(suppl 1):S420.
16. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis. 2009;15:375-382.
17. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-459. (Pubitemid 38182302)
18. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099-1105; quiz 1340-1341.
19. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut. 1988;29:206-217. (Pubitemid 18078890)
20. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983-989.
21. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530. (Pubitemid 34117002)
22. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512. (Pubitemid 39311530)
23. Lichtenstein GR. Emerging prognostic markers to determine Crohn's disease natural history and improve management strategies: a review of recent literature. Gastroenterol Hepatol (N Y). 2010;6:99-107.
24. Sipponen T, Kärkkäinen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221-1229.
25. Rimola J, Ordás I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2010 Nov 8. Epub ahead of print.
26. Rimola J, Rodriguez S, García-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut. 2009;58:1113-1120.
27. Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease. Inflamm Bowel Dis. 2011;17:1073-1080.
28. D'Haens GR, Fedorak R, Lémann M, et al; IOIBD Membership. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009;15:1599-1604.
29. Keohane J, O'Mahony C, O'Mahony L O'Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? AmJ Gastroenterol. 2010;105:1788, 1789-1794, quiz 1795.
30. Camilleri M. Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel disease. Gut. 2011;60:425-428.
31. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478-2485.
32. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57:893-902. (Pubitemid 351919522)
33. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009;15:1-8.
34. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132:66-75; quiz 432-433.
35. Kruis W, Kiudclis G, Rácz I, et al; International Salofalk OD Study Group. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009;58:233-240.
36. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95-102. (Pubitemid 46096842)
37. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009;137:1934-1943.e1-e3.
38. Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1992; 102:1647-1653.
39. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990;98:811-818.
40. Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology. 1999;116:294-300.
41. Mañosa M, Naves JE, Leal C, et al. Does methotrexate induce mucosal healing in Crohn's disease? Inflamm Bowel Dis. 2010;16:377-378.
42. Laharie D, Reffet A, Belleannee G, et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther. 2011;33:714-721.
43. Sandborn WJ, Van O EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology. 1995;109:1808-1817.
44. D'Haens GR, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology. 1997;112:1475-1481. (Pubitemid 27181370)
45. D'Haens GR, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc. 1999;50:667-671. (Pubitemid 29518050)
46. D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology. 2008;135:1123-1129.
47. Colombel JF, Sandborn WJ, Reinisch W, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
48. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413. (Pubitemid 38182297)
49. Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
50. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol. 2003;98: 833-888.
51. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis. 2004;36:342-347. (Pubitemid 41115465)
52. D'Haens GR, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999;116:1029-1034. (Pubitemid 29203012)
53. Geboes K, Rutgeerts P, Opdenakker G, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin. 2005;21:1741-1754. (Pubitemid 41667241)
54. Van Dullemen HM, Van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
55. Rutgeerts P, D'Haens G, Van Assche G, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease. First results of the EXTEND trial. Gastroenterology. 2009;136:A-116.
56. Sandborn WJ, Panaccione R, Thakkar R, et al. Crohn's disease mucosal healing in adalimumab-treated patients is affected by disease duration: results from EXTEND. Gastroenterology. 2010;138:S-164.
57. Colombel JF, Lémann M, Bouhnik Y, et al. Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol: Week 10 and 54 results of the MUSIC trial. Gastroenterology. 2010;138:S-166.
58. Louis E, Vernier-Massouille G, Grimaud JC, et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology. 2009; 136:A-146.
59. Sandborn WJ, Colombel JF, Enns R, et al; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353:1912-1925.
60. Targan SR, Feagan BG, Fedorak RN, et al; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672-1683.
61. Rutgeerts P, Allison MC, Cortot A, et al. Effects of natalizumab on gut healing in a phase 3 study of active Crohn's disease therapy (ENACT-1). Gastroenterology. 2004;126(suppl 2):A-208.